ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IXHL / news
ACET (32) LITS (43) RMTI (23) RNAZ (35) ⌘ Pro Terminal →

Why IXHL Stock dropped -5.56% Today — RQD Quant Desk Flash

$2.38 -5.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.35

Incannex Healthcare Inc. (IXHL) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $29.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IXHL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IXHL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Incannex Healthcare Inc. (NASDAQ: IXHL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.38 (-5.56% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IXHL ranks #544 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IXHL compare to ACET and LITS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IXHL carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACET (Adicet Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and LITS (Lite Strategy Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $29.4M). Among the 5-stock peer group, IXHL leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IXHL?
▼

Per IXHL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001873875), Incannex Healthcare Inc. generated $66.6M in revenue (+554976.7% YoY), -$46.9M in net income, and -$12.5M in free cash flow against $75.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.35 (-1.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (9)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.2% Base Target
$16 Bull$2 Base$2 Bear
📬 FREE IXHL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IXHL)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY IXHL SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$2.86-3.5% Next Q
Q2 (-2Q)
42
Grade D$2.76-1.8% Next Q
Q3 (-1Q)
40
Grade D$2.71-12.2% Next Q
Current
37
Grade D-$2.38-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IXHL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IXHL currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.11) and Max Pain ($2.50) forces dealer call-delta covering toward $15.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IXHL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IXHL Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why IXHL Stock dropped -5.56% Today — RQD Quant Desk Flash

Incannex Healthcare Inc. (IXHL) dropped -5.56% to $2.38, trading at 2% of its 52-week range ($2.38 – $14.91). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($2.38 – $14.91) with RSI-14 at 27 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±10.3% around $2.38 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IXHL Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IXHL)

  • ✓Walkthrough of IXHL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IXHL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.89%🛡️ HOLDING TREND SUPPORT
2026-11-04O $2.52H $2.52L $2.38C $2.38VOL 148.9K
RES: $3.64SUP: $2.18SMA50: $3.11SMA200: $4.07
$11.60$9.10$6.60$4.10$1.60RES $3.64SUP $2.18$2.382026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IXHL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IXHL Butterfly Map → + Track IXHL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +554976.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IXHL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IXHL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IXHL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IXHL)

Health Care Rank #544 of 1015 ⚔️ ACET vs IXHL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IXHL vs. ACET, LITS, RMTI, RNAZ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Incannex Healthcare Inc. (IXHL) ranks #544 by composite RQD confidence (37/100, grade D-) and #794 by equity capitalization ($29.9M). Within this direct 5-issuer industry benchmark cohort, IXHL leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. LITS currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with IXHL at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IXHL ACTIVE
Incannex Healthcare Inc.
D- 37/100 — — -35.0% -5.56% $29.9M Benchmark Subject
ACET
Adicet Bio Inc.
E 32/100 — — -35.0% -6.43% $30.0M /acet-vs-ixhl →
LITS
Lite Strategy Inc.
D- 43/100 — — -18.9% -13.60% $29.4M /lits-vs-ixhl →
RMTI
Rockwell Medical Inc.
E 23/100 — 16.9% -10.6% -2.26% $27.9M /rmti-vs-ixhl →
RNAZ
TransCode Therapeutics Inc.
D- 35/100 — — -35.0% 0.00% $27.6M /rnaz-vs-ixhl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001873875 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Incannex Healthcare Inc. (IXHL) reported GAAP revenue of $66.6M (+554976.7% vs. FY2024 revenue of $12.0K , and -52.1% cumulative change since FY2023) , GAAP net income of -$46.9M, operating cash flow of -$12.5M, and free cash flow of -$12.5M (+22.3% YoY). On the balance sheet, IXHL closed FY2025 with $75.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $66.6M -$46.9M -$12.5M -$12.5M $75.0M —
FY2024 (FY) 2024-06-30 $12.0K -$18.5M -$15.8M -$16.1M $11.1M $2.4M
FY2023 (FY) 2023-06-30 $139.1M -$48.8M -$10.7M -$10.7M — —

3. IXHL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IXHL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Incannex Healthcare Inc. (NASDAQ: IXHL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.38 (-5.56% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IXHL ranks #544 in composite RQD confidence.

How does IXHL compare to ACET and LITS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IXHL carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACET (Adicet Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and LITS (Lite Strategy Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $29.4M). Among the 5-stock peer group, IXHL leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IXHL?

Per IXHL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001873875), Incannex Healthcare Inc. generated $66.6M in revenue (+554976.7% YoY), -$46.9M in net income, and -$12.5M in free cash flow against $75.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IXHL trading relative to its 50-day, 200-day, and 52-week technical levels?

IXHL last traded at $2.38 (-5.56% on volume of 148,894 shares), positioning the stock -23.47% below its 50-day simple moving average ($3.11) and -41.52% below its 200-day simple moving average ($4.07). Across its 52-week range of $2.38 to $14.91, IXHL sits at the 0.0% percentile with a 14-day RSI of 27.0 (OVERSOLD (<32)) and an implied next-earnings move of ±10.3% ($2.13 to $2.63).

Direct Sub-Reports: IXHL RQD Cockpit IXHL 12M Forecast IXHL Earnings & Move IXHL Dividends & DRIP IXHL Insiders & 13F IXHL Whale Options IXHL Profit Sankey IXHL News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

IXHL — Incannex Healthcare Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Incannex Healthcare Inc. (IXHL) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.38 (-5.56% 1D, market capitalization $29.9M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Incannex Healthcare Inc. (IXHL) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Incannex Healthcare Inc. (IXHL) reported $66.6M in annual revenue (up from $12.0K in FY2024, +554976.7% YoY) and -$46.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($139.1M revenue, -$48.8M net income) through FY2025, IXHL scaled operating cash flow to -$12.5M and free cash flow to -$12.5M, backed by $75.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.38 – $14.91 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), IXHL carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can IXHL sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $66.6M and free cash flow of -$12.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IXHL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IXHL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Incannex Healthcare Inc. (IXHL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IXHL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IXHL Bull vs. Bear Conversation Board — What's Your Call at $2.38?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IXHL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IXHL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $3.15 (+25.0%)
📌 Pinned Debate

Reported cash rose to $68.9M in FY 2025 from $2.1M in FY 2024, and the news feed cites a $68.4M runway.

Don't sleep on IXHL's setup in Health Care. Reported cash rose to $68.9M in FY 2025 from $2.1M in FY 2024, and the news feed cites a $68.4M runway.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (37/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 3/20 institutional whale-flow stock at $2.52 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.99 (-21.0%)
Spot @ $2.52

Reported revenue is $0.0M in every listed period, net losses ran -$46.9M in FY 2025, and the RQD rating scores the company 37 out of 10

Fading this rally in IXHL at $2.52. Reported revenue is $0.0M in every listed period, net losses ran -$46.9M in FY 2025, and the RQD rating scores the company 37 out of 100 with ROIC at -35%.. With a beta of 1.0 and the stock sitting at $2.52 (52-wk range $2.49–$14.91), the easy multiple expansion is already priced in.

LIVE TAPE